Vineet Laboratories Share Price
Sector: Biotechnology & Drugs
30.69 +0.60 (1.99%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
30.69
Today’s High
30.69
52 Week Low
25.35
52 Week High
78.48
31.21 +0.61 (1.99%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
31.21
Today’s High
31.21
52 Week Low
26.51
52 Week High
78.45
Key Metrics
- Market Cap (In Cr) 28.29
- Beta 0.56
- Div. Yield (%) 0
- P/B 1.93
- TTM P/E -
- Peg Ratio -
- Sector P/E 22.67
- D/E 0.03
- Open Price 30.69
- Prev Close 30.09
Vineet Laboratories Analysis
Price Analysis
-
1 Week7.56%
-
3 Months-2.8%
-
6 Month-48.61%
-
YTD-48.26%
-
1 Year-47.89%
Risk Meter
- 67% Low risk
- 67% Moderate risk
- 67% Balanced Risk
- 67% High risk
- 67% Extreme risk
Vineet Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 75
- Selling/ General/ Admin Expenses Total
- 5.34
- Depreciation/ Amortization
- 2.5
- Other Operating Expenses Total
- 15.7
- Total Operating Expense
- 93.78
- Operating Income
- -18.78
- Net Income Before Taxes
- -20.78
- Net Income
- -20.19
- Diluted Normalized EPS
- -21.9
- Period
- 2025
- Total Assets
- 94.54
- Total Liabilities
- 79.89
- Total Equity
- 14.65
- Tangible Book Valueper Share Common Eq
- 15.89
- Period
- 2025
- Cashfrom Operating Activities
- 11.49
- Cashfrom Investing Activities
- -3.18
- Cashfrom Financing Activities
- -8.23
- Net Changein Cash
- 0.08
- Period
- 2024
- Total Revenue
- 150.59
- Selling/ General/ Admin Expenses Total
- 6.38
- Depreciation/ Amortization
- 2.52
- Other Operating Expenses Total
- 23.09
- Total Operating Expense
- 145.91
- Operating Income
- 4.68
- Net Income Before Taxes
- 0.36
- Net Income
- 1.03
- Diluted Normalized EPS
- 1.11
- Period
- 2024
- Total Assets
- 116.87
- Total Liabilities
- 82.15
- Total Equity
- 34.72
- Tangible Book Valueper Share Common Eq
- 37.67
- Period
- 2024
- Cashfrom Operating Activities
- -11.43
- Cashfrom Investing Activities
- 0.33
- Cashfrom Financing Activities
- 10.69
- Net Changein Cash
- -0.4
- Period
- 2023
- Total Revenue
- 212.29
- Selling/ General/ Admin Expenses Total
- 6
- Depreciation/ Amortization
- 2.37
- Other Operating Expenses Total
- 26.3
- Total Operating Expense
- 207.01
- Operating Income
- 5.29
- Net Income Before Taxes
- 2.03
- Net Income
- 1.25
- Diluted Normalized EPS
- 1.36
- Period
- 2023
- Total Assets
- 115.85
- Total Liabilities
- 82.17
- Total Equity
- 33.68
- Tangible Book Valueper Share Common Eq
- 36.54
- Period
- 2023
- Cashfrom Operating Activities
- 4.53
- Cashfrom Investing Activities
- -3.68
- Cashfrom Financing Activities
- 10.66
- Net Changein Cash
- 11.51
- Period
- 2022
- Total Revenue
- 191.17
- Selling/ General/ Admin Expenses Total
- 4.91
- Depreciation/ Amortization
- 2.02
- Other Operating Expenses Total
- 27.47
- Total Operating Expense
- 179.94
- Operating Income
- 11.23
- Net Income Before Taxes
- 9.35
- Net Income
- 6.64
- Diluted Normalized EPS
- 7.2
- Period
- 2022
- Total Assets
- 133.32
- Total Liabilities
- 100.1
- Total Equity
- 33.22
- Tangible Book Valueper Share Common Eq
- 36.03
- Period
- 2022
- Cashfrom Operating Activities
- 7.63
- Cashfrom Investing Activities
- -3.68
- Cashfrom Financing Activities
- 11.96
- Net Changein Cash
- 15.91
- Period
- 2021
- Total Revenue
- 243.48
- Selling/ General/ Admin Expenses Total
- 5.57
- Depreciation/ Amortization
- 1.81
- Other Operating Expenses Total
- 31.65
- Total Operating Expense
- 237.14
- Operating Income
- 6.34
- Net Income Before Taxes
- 4.06
- Net Income
- 1.78
- Diluted Normalized EPS
- 1.93
- Period
- 2021
- Total Assets
- 108.74
- Total Liabilities
- 82.13
- Total Equity
- 26.61
- Tangible Book Valueper Share Common Eq
- 28.87
- Period
- 2021
- Cashfrom Operating Activities
- -8.71
- Cashfrom Investing Activities
- -7.81
- Cashfrom Financing Activities
- 18.62
- Net Changein Cash
- 2.1
- Period
- 2020
- Total Revenue
- 0
- Selling/ General/ Admin Expenses Total
- 0
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0.01
- Total Operating Expense
- 0.01
- Operating Income
- -0.01
- Net Income Before Taxes
- -0.01
- Net Income
- -0.01
- Diluted Normalized EPS
- -0.01
- Period
- 2020
- Total Assets
- 0.4
- Total Liabilities
- 0
- Total Equity
- 0.4
- Tangible Book Valueper Share Common Eq
- 0.43
- Period
- 2020
- Period
- 2025-03-31
- Total Revenue
- 14.08
- Selling/ General/ Admin Expenses Total
- 1.35
- Depreciation/ Amortization
- 0.66
- Other Operating Expenses Total
- 3.2
- Total Operating Expense
- 25.78
- Operating Income
- -11.7
- Net Income Before Taxes
- -11.22
- Net Income
- -10.53
- Diluted Normalized EPS
- -11.4
- Period
- 2025-03-31
- Total Assets
- 94.54
- Total Liabilities
- 79.89
- Total Equity
- 14.65
- Tangible Book Valueper Share Common Eq
- 15.89
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 11.49
- Cashfrom Investing Activities
- -3.18
- Cashfrom Financing Activities
- -8.23
- Net Changein Cash
- 0.08
- Period
- 2024-12-31
- Total Revenue
- 18.1
- Selling/ General/ Admin Expenses Total
- 1.21
- Depreciation/ Amortization
- 0.62
- Other Operating Expenses Total
- 3.75
- Total Operating Expense
- 22.85
- Operating Income
- -4.76
- Net Income Before Taxes
- -5.67
- Net Income
- -5.71
- Diluted Normalized EPS
- -6.19
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 18.96
- Selling/ General/ Admin Expenses Total
- 1.29
- Depreciation/ Amortization
- 0.62
- Other Operating Expenses Total
- 4.53
- Total Operating Expense
- 19.88
- Operating Income
- -0.92
- Net Income Before Taxes
- -1.71
- Net Income
- -1.83
- Diluted Normalized EPS
- -1.98
- Period
- 2024-09-30
- Total Assets
- 106.53
- Total Liabilities
- 75.77
- Total Equity
- 30.77
- Tangible Book Valueper Share Common Eq
- 33.37
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 5.81
- Cashfrom Investing Activities
- -0.08
- Cashfrom Financing Activities
- -5.85
- Net Changein Cash
- -0.13
- Period
- 2024-06-30
- Total Revenue
- 23.86
- Selling/ General/ Admin Expenses Total
- 1.48
- Depreciation/ Amortization
- 0.61
- Other Operating Expenses Total
- 4.22
- Total Operating Expense
- 25.27
- Operating Income
- -1.4
- Net Income Before Taxes
- -2.17
- Net Income
- -2.13
- Diluted Normalized EPS
- -2.31
- Period
- 2024-06-30
- Total Assets
- 111.11
- Total Liabilities
- 78.51
- Total Equity
- 32.59
- Tangible Book Valueper Share Common Eq
- 35.35
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 37.05
- Selling/ General/ Admin Expenses Total
- 1.82
- Depreciation/ Amortization
- 0.67
- Other Operating Expenses Total
- 5.41
- Total Operating Expense
- 34.31
- Operating Income
- 2.74
- Net Income Before Taxes
- 1.43
- Net Income
- 1.92
- Diluted Normalized EPS
- 2.1
- Period
- 2024-03-31
- Total Assets
- 116.87
- Total Liabilities
- 82.15
- Total Equity
- 34.72
- Tangible Book Valueper Share Common Eq
- 37.67
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -11.43
- Cashfrom Investing Activities
- 0.33
- Cashfrom Financing Activities
- 10.69
- Net Changein Cash
- -0.4
- Period
- 2023-12-31
- Total Revenue
- 32.65
- Selling/ General/ Admin Expenses Total
- 1.77
- Depreciation/ Amortization
- 0.63
- Other Operating Expenses Total
- 5.22
- Total Operating Expense
- 33.92
- Operating Income
- -1.27
- Net Income Before Taxes
- -2.33
- Net Income
- -2.07
- Diluted Normalized EPS
- -2.24
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Vineet Laboratories Technical
Moving Average
SMA
- 5 Day29.49
- 10 Day29.67
- 20 Day30.57
- 50 Day31.56
- 100 Day36.6
- 300 Day46.5
Vineet Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Aryavan Enterprise
- 45
- -0.02
- -0.04
- 69.74
- 31.57
- 25.92
- Concord Drugs
- 36
- 4.79
- 15.35
- 44.96
- 26.1
- 35.33
- Vineet Laboratories
- 30.69
- 0.6
- 1.99
- 78.48
- 25.35
- 28.29
- Ishita Drugs And Industries
- 82.15
- -1.85
- -2.2
- 104.75
- 62.35
- 24.57
- Zenith Health Care
- 4.4
- 0
- 0
- 6.87
- 3.82
- 23.65
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Aryavan Enterprise
- 14.55
- 1.06
- 4.77
- 3.29
- Concord Drugs
- 90.26
- 0.9
- 4.46
- 2.64
- Vineet Laboratories
- -
- 1.89
- -6.99
- -1.09
- Ishita Drugs And Industries
- 28.32
- 2.28
- 8.63
- 5.45
- Zenith Health Care
- 340.77
- 3.21
- 3.1
- 1.46
Vineet Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 12-May-25
- Audited Results
- 12-Feb-25
- Quarterly Results
- 13-Nov-24
- Quarterly Results
- 13-Aug-24
- Quarterly Results
- 29-May-24
- Audited Results
- 12-Feb-24
- Quarterly Results
- 10-Nov-23
- Quarterly Results
- 12-Aug-23
- Quarterly Results
- 29-May-23
- Audited Results
- 14-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 27-Sept-24
- 12-Sept-24
- AGM
- 27-Dec-23
- 22-Nov-23
- POM
- 28-Sept-23
- 11-Sept-23
- AGM
- 28-Sept-22
- 30-Aug-22
- AGM
- 19-Dec-20
- 16-Nov-20
- AGM
- 30-Sept-19
- 07-Sept-19
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 30-May-22
- 20-Sept-22
- 19-Sept-22
- 1


